Fresenius SE & Co. KGaA (FRA:FRE) Given a €30.00 Price Target by Credit Suisse Group Analysts

Fresenius SE & Co. KGaA (FRA:FRE – Get Rating) received a €30.00 ($30.93) price objective from stock analysts at Credit Suisse Group in a research report issued to clients and investors on Friday, Borsen Zeitung reports. Credit Suisse Group’s price objective would indicate a potential upside of 23.81% from the stock’s previous close.

Several other research firms also recently weighed in on FRE. Jefferies Financial Group set a €30.00 ($30.93) price objective on Fresenius SE & Co. KGaA in a report on Monday, July 25th. Barclays set a €35.00 ($36.08) price objective on Fresenius SE & Co. KGaA in a report on Friday. JPMorgan Chase & Co. set a €33.30 ($34.33) price objective on Fresenius SE & Co. KGaA in a report on Monday, July 18th. set a €36.00 ($37.11) price target on Fresenius SE & Co. KGaA in a research note on Friday, July 29th. Finally, Warburg Research set a €42.00 ($43.30) price target on Fresenius SE & Co. KGaA in a research note on Friday.

Fresenius SE & Co. KGaA Price Performance

Shares of FRE stock traded up €0.15 ($0.15) during trading hours on Friday, hitting €24.23 ($24.98). The stock had a trading volume of 1,383,900 shares. Fresenius SE & Co. KGaA has a twelve month low of €60.16 ($62.02) and a twelve month high of €80.00 ($82.47). The stock’s 50 day moving average is €28.51 and its 200 day moving average is €31.96.

About Fresenius SE & Co. KGaA

(Get Rating)

Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.